Navigation Links
ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server
Date:8/11/2009

FREMONT, Calif., Aug. 11 /PRNewswire/ -- ValGenesis, Inc., a leading provider of Validation Lifecycle Management solutions, announces the worldwide availability of Microsoft SharePoint Server integration with the latest version of ValGenesis 2.0 for increased enterprise productivity specifically for regulated Pharmaceuticals, Biotech and Medical Devices companies. This offering will seamlessly provide global access, retrieval and storage of corporate validation data and documents generated by ValGenesis within Microsoft SharePoint Server. Companies will be able to keep all the business-critical and compliance data in one central location leveraging real-time reporting and robust search functionality of Microsoft SharePoint Server. ValGenesis Integration with SharePoint follows a familiar usability-driven scenario resulting in an end-to-end secured, 100% paperless, validation lifecycle management solution provided by these two complementary technologies.

"Many Life Sciences companies have standardized on Microsoft SharePoint Server for document management and want the flexibility to leverage this investment. ValGenesis continues to offer state of the art ValGenesis software and now allows customers to use Microsoft SharePoint Server to provide validation data and documents throughout the enterprise through this integration. ValGenesis offers SharePoint users strengthened return on investment and additional usability, functionality and productivity," said Siva Samy, Ph.D., ValGenesis Chief Product Strategist.

About ValGenesis

ValGenesis offers an innovative software platform that serves as the foundation for compliance-based validation life cycle management in regulated companies. ValGenesis is the first Enterprise application to automate the validation lifecycle of GxP systems and to provide 360-degree visibility to the corporate validation process. ValGenesis is designed to fully conform to FDA 21 CFR Part 11 compliance requirements. Through an industry peer review committee, the Parenteral Drug Association (PDA), awarded ValGenesis the prestigious New Innovative Technology award.

    For more information:

    Mike Beaudro, 510-445-0505, mike.beaudro@valgenesis.com
    Website:http://www.valgenesis.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE ValGenesis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... January 11, 2017 , ... While the most acute effects ... becoming increasingly clear that the evolution and transmission dynamics of resistance gene dissemination ... study of clinical resistance, has vastly underestimated these reservoirs of resistance genes. ...
(Date:1/11/2017)... ... January 11, 2017 , ... For ... difference when navigating the challenges young businesses face. With the second installment of ... and experience of Geoff DiMasi, Founder and Principal of interactive design agency, P’unk ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... business development professional has joined its team. Bernhard Bartylla will lead European initiatives ... working with Bernhard to introduce ACOMP and ARGEN to European manufacturers and researchers. ...
(Date:1/11/2017)... Md. , Jan. 11, 2017  GenVec, ... gene delivery company, announced today that its chief ... present a talk entitled  "AdenoVerse™ platform for translational ... the Biotech Showcase at the upcoming Phacilitate Cell ... Miami , Florida.  Dr. Brough,s presentation ...
Breaking Biology Technology:
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
Breaking Biology News(10 mins):